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Background: Bilirubin (BIL) has been recognized as an endogenous antioxidant that shows a protective effect for
cardiorenal diseases. We investigated whether administration of BIL had a protective effect on cyclosporine
(CsA)-induced nephropathy (CIN), and examined the effects of BIL on the oxidative stress and apoptosis.
Methods: BIL was pretreated intraperitoneally three times for a week (60 mg/kg), and CsA was injected for 4 weeks
(15 mg/kg/day, subcutaneous). Proximal tubular epithelial (HK2) cells were pretreated with 0.1mg/ml of BIL for
24 hours, and then treated with 20 μM of CsA for another 24 hours.
Results: CsA induced marked increases in urine kidney injury molecule-1 (Kim-1) and neutrophil gelatinase-
associated lipocalin (NGAL) concentrations (P < 0.05). BIL reduced urine Kim-1 in CIN (P < 0.05), while urine NGAL
exhibited a decreasing tendency. In CsA-treated rat kidneys, the protein expression of NOX4 and p22phox was
reduced by BIL (P < 0.05). BIL ameliorated CsA-induced arteriolopathy, tubulointerstitial fibrosis, tubular injury, and
the apoptosis examined by TUNEL assay (P < 0.01). In HK2 cells, BIL reduced intracellular reactive oxygen species in
CsA-treated cells. CsA increased the protein expression of bax, cleaved caspase-9, caspase-3 and the activity of
caspase-3; however, the anti-apoptotic bcl-2 protein was reduced. These changes were recovered by BIL (P < 0.05).
Conclusions: The direct administration of BIL protected against CsA-induced tubular injury via inhibition of
oxidative stress and apoptosis.
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Bilirubin (BIL) has been shown to exert a protective effect
for cardiorenal diseases. A high-normal concentration of
serum BIL was related to a decreased risk of cardiovascu-
lar disease [1-3]. Also, BIL showed beneficial effects in
diabetic nephropathy, ischemia reperfusion injury, and
contrast-induced nephropathy [4-6]. BIL is a breakdown
product of heme-containing proteins such as hemoglobin
in aging red blood cells. Heme oxygenase-1 (HO-1), the
rate-limiting enzyme involved in heme catabolism, con-
verts heme to biliverdin, free ferrous iron, and carbon
monooxide. Subsequently, biliverdin is rapidly converted
to BIL by biliverdin reductase [7]. Recently, accumulating
evidence has suggested that HO-1 and its product BIL* Correspondence: mednep@snubh.org
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reproduction in any medium, provided the ormay be important endogenous agents with cytoprotective
activity against oxidative stress injury [5-9].BIL is known
as an effective radical scavenger, and inhibits the activity of
nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase [5,10]. BIL had been showed the antioxidant and
cytoprotective effects in angiotensin II-mediated vasocon-
striction and DNA damage [11]. However, few studies have
reported the anti-apoptotic effect of BIL [6,12,13].
Cyclosporine (CsA) has been commonly used as an
immunosuppressant in organ transplantation and auto-
immune diseases. However, chronic use of CsA has a toxic
effect on the kidney. CsA induces the activation of the
intrarenal renin–angiotensin-aldosterone system [14,15],
which causes renal vasoconstriction and hypoxia. In CsA-
induced nephropathy (CIN), the production of reactive
oxygen species (ROS) is increased in the kidney [16,17]. In
addition, CsA may activate a NADPH oxidase that re-
leases superoxide anion [18]. CsA activates the expression. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lar and interstitial cells, resulting in tubular atrophy [19-21].
We investigated whether intraperitoneal administration
of BIL had a protective effect on CIN. We also examined
the molecular mechanism underlying the effects of BIL on
the oxidative stress and apoptosis in CIN.
Methods
Cell culture
HK-2 cells (ATCC CRL-2190), which are proximal tubular
epithelial cells derived from normal human kidney tissue,
were cultured using Renal Epithelial Basal Medium (Lonza
Walkersville Inc., Walkersville, MD, USA) with reco-
mmended supplements included in the REGM Singlequot
Bulletkit. The cells were fed two to three times weekly and
subcultivated via trypsinization when near confluence.
HK-2 cells between passages 10 and 25 were used for
these experiments.
Cell treatment
Cells were grown to 80% confluence before treatment
for all experiments. CsA (Sigma, St. Louis, MO, USA)
was prepared as a stock solution (4.2 mM) by dissolving
5 mg of the powder in 1 ml of absolute ethanol. This
stock was further diluted in growth medium before
treatment and added to the main cell growth media. BIL
(Sigma #B4125, St. Louis, MO, USA) was dissolved in
Dimethyl sulfoxide.
The cells were divided into three groups: control cells,
CsA-treated cells, and CsA-treated cells with BIL pre-
treatment (BIL + CsA). On the day prior to an experi-
ment, the cells were pre-treated with 0.1 mg/ml of BIL
for 24 hours. The cells were then treated with 20 μM of
CsA for another 24 hours. Only bilirubin treated cells
(BIL) was evaluated for the expression of caspase-3.
Animal experiments
Fifteen male Sprague–Dawley rats (Orient Bio Inc.,
Seongnam, Korea) weighing 200 to 250 g were housed
in individual cages in a temperature- and light-controlled
environment. The rats received a low-salt diet (0.05% so-
dium; Samtako, Osan, Korea) and were allowed free access
to water. This study was approved by, and conducted
according to the guidelines of, the Seoul National Univer-
sity Bundang Hospital Committee of animal experiment.
After one week on the low-salt diet, the rats were assigned
to experimental groups (N = 5/group). BIL was injected
intraperitoneally three times for one week (60 mg/kg) be-
fore the administration of CsA. The BIL was dissolved in
DMSO to a final concentration of 20 mg/ml. The vehicle
consisted of DMSO. CsA (Novartis, East Hanover, NJ,
USA) was diluted in olive oil to a final concentration of15 mg/ml. The following groups were studied: (1) Vehicle
(VH) The rats received a subcutaneous (SC) injection of
olive oil 1 ml/kg/day plus a intraperitoneal injection of
DMSO; (2) Bilirubin (BIL): The rats received a SC injection
of olive oil 1 ml/kg/day plus a intraperitoneal injection of
bilirubin (60 mg/kg) dissolved with DMSO (3) CsA group:
The rats received a SC injection of CsA 15 mg/kg/day plus
a intraperitoneal injection of DMSO; (4) BIL +CsA group:
The rats received a SC injection of CsA 15 mg/kg/day plus
a a intraperitoneal injection of BIL (60 mg/kg) dissolved
with DMSO.
After 4 weeks, the rats were anesthetized with zolazepam
and xylazine, their blood was sampled, and their kidneys
were collected. The left kidney from each rat was fixed
in 10% phosphate-buffered formalin for morphologic ana-
lyses. The right kidneys were collected for western blotting.Physiologic measurements
At the end of experiments, the rats were weighed and placed
in metabolic cages, and urine was collected for 24 h. The
urine volume was measured, and the albumin concentration
was determined by ELISA kit (Exocell, Philadelphia, PA,
USA). Urinary albumin excretion was calculated in terms of
milligrams of albumin per 24 hours. Creatinine levels in the
serum (Bioassay Systems, Hayward, CA, USA) and urine
(Exocell, Philadelphia, PA, USA) were also measured using
ELISA kit. CsA blood level was measured by a direct CsA
radioimmunoassay kit (Immunotech, Czech Republic).
Serum LDH was measured by using an automatic analyzer
(ADVIA 2400, Siemens, USA). Bilirubin was measured by
quantitative colorimetric assay (Bioassay systems #DIBR-
180, CA, USA). Systolic blood pressure (SBP) wasmonitored
with a tail cuff sphygmomanometer (Panlab S.L., Barcelona,
Spain). SBP was recorded as themean value of three separate
measurements that were obtained at each session.The measurement of kidney injury molecule-1 (Kim-1)
and neutrophil gelatinase-associated lipocalin (NGAL) in
urine
The urine samples were centrifuged immediately after be-
ing collected, and the supernatant was preserved at −70°C
until use. The Kim-1 and NGAL were examined with the
accompanying procedural instructions by using a Rat Kim-
1 ELISA Kit (Bioassay Works LLC, Ijamsville, MD, USA)
and a Rat NGAL ELISA Kit (BioPorto Diagnosis A/S,
Denmark) in Sandwich ELISA analysis, respectively. The
frozen and preserved samples were thawed at room tem-
perature. The average values were derived in duplicate for
all of the samples. The standard curve and the absorbance
of the samples were measured with a micro-plate reader
(Bio-Rad Laboratories, Inc., CA, USA) at a wavelength of
450 nm with reference reading at 650 nm.
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The tissue samples used for light microscopy and immu-
noperoxidase staining were fixed in formalin and embed-
ded in paraffin. Three-micrometer sections were stained
with periodic acid-Schiff (PAS) or Masson Trichrome
(MT). The histologic findings were subdivided into three
categories: arteriolopathy, tubulointerstitial fibrosis, and
tubular injury. Findings ascribed to tubulointerstitial
fibrosis included matrix expansion with tubular distor-
tion and basement membranes thickening. Tubular in-
jury consisted of cellular and intracellular vacuolization,
tubular collapse and tubular distension. More than 20
consecutive fields were examined under × 200 magnifica-
tion and the results were averaged. The extent of tubulo-
interstitial fibrosis and tubular injury in cortical tubules were
graded using the following score: 0 = normal interstitium,
0 = normal interstitium, 0.5 = <5% of areas injured, 1 = 5
to 15%, 1.5 = 16 to 25%, 2 = 26 to 35%, 2.5 = 36 to 45%,
and 3 = > 45%. Arteriolopathy was determined by counting
at least 100 glomeruli. During this counting, arteriolopathy
was recorded as present or absent. Arteriolopathy consisted
of the hyalinization and destruction of afferent arterioles.
The results are expressed as the percentage of juxtaglo-
merular affected arterioles over total number of arterioles:
0 = no arterioles injured, 0.5 = <15%; 1 = 15 to 30%, 1.5 = 31
to 45%, 2 = 46 to 60%, 2.5 = 61 to 75%, and 3 = >75%.
Western blot analysis
Western blotting was performed as previously described
[22]. The kidney tissue was homogenized, and the lysates of
kidney tissue and HK-2 cell were prepared. Protein concen-
trations were measured using a bicinchoninic acid protein
assay kit (Thermo Fisher Scientific, Rockford, IL, USA).
The samples were run on SDS-polyacrylamide mini-gels
(Bio-Rad Mini Protean III). The proteins were transferred to
nitrocellulose membranes by electroelution. NOX-4 (Santa
Cruz Biotech, Santa Cruz, CA), p22phox (Santa Cruz Bio-
tech, Santa Cruz, CA), bcl-2 (Cell Signaling Technology,
Beverly, MA), bax (Santa Cruz Biotech, Santa Cruz, CA),
caspase-9 (BD Bioscience, Franklin Lakes, NJ), caspase-3
(Cell Signaling Technology, Danvers, MA), β-actin (Santa
Cruz Biotech, Santa Cruz, CA), were used for this study. In-
cubation with horseradish peroxidase-conjugated secondary
antibodies (Santa Cruz Biotech, Santa Cruz, CA, USA) was
followed by band visualization using an enhanced chemilu-
minescence substrate (Thermo Fisher Scientific, Rockford,
IL, USA). The band densities were quantified by densito-
metry (GS-700 Imaging Densitometry, Bio-Rad, Hercules,
CA, USA). To facilitate comparisons, the densitometry
values were normalized by β-actin expression.
Detection of intracellular reactive oxygen species (ROS)
Oxidation-sensitive 2′,7′-dichlorofluorescein diacetate
(DCFH-DA) (Sigma, St. Louis, MO, USA) was used todetermine the intracellular production of reactive oxygen
species (ROS). The cells were loaded with DCFH-DA at
a final concentration of 10 μM, incubated at 37°C for
30 min, washed with phosphate-buffered saline, and re-
moved from the dishes by scraping. The fluorescence
intensity was measured by fluorescence spectrophotom-
eter at excitation and emission wavelengths of 490 nm
and 526 nm, respectively.
Detection of apoptosis
Apoptosis was assessed by terminal deoxynucleotidyl
transferase-mediated uridine triphosphate nick-end labeling
(TUNEL), following which the apoptotic cells were counted.
Apoptotic cells were defined by chromatin condensation or
nuclear fragmentation. Apoptosis was detected in the speci-
mens using the In Situ Cell Death Detection Fluorescein Kit
(Roche Applied Science, Mannheim, Germany) according
to the manufacturer’s protocol. The same slides were stained
with 4′,6′-diamidino-2-phenyindole (DAPI) in phosphate-
buffered saline to reveal total nuclei. For apoptotic nuclei
counting, cells from at least 10 consecutive fields under ×
400 magnification were counted. The final count was
expressed as the percentage of total cells counted by fluores-
cence microscopy (Carl Zeiss, Jena, Germany). In addition,
TUNEL-positive cells were counted in the cortical tubular
cells in 10 consecutive fields under × 400 magnification.
Caspase-3 activity assayed through the use of the
Caspase-3/CPP32 Fluorometric Assay Kit (BioVision,
Mountain View, CO, USA). Cells were incubated in cell
lysis buffer and centrifuged at 14,000 rpm, and the superna-
tants were incubated with DEVD-AFC (a specific substrate
for caspase-3) at 37°C for 1 hour. Subsequently, the activity
was assayed through the use of a fluorescence microplate
reader (Molecular Devices, Sunnyvale, CA, USA).
Statistical analyses
The results are presented as the mean ± standard deviation
of mean. The statistical analyses were performed using SPSS
(version 18.0. for Windows; SPSS Inc., Chicago, IL, USA).
The comparisons between groups were conducted with an
analysis of variance followed by a Tukey. For comparisons of
two groups, data were analyzed using a Student’s t-test or a
Mann–Whitney test. The level of statistical significance was
set as P< 0.05.
Results
Intraperitoneal injection of bilirubin (BIL) significantly
increase the plasma BIL
Total plasma bilirubin concentration was meaured after an
intraperitoneal injection of bilirubin. After the administra-
tion of bilirubin intraperitoneally (60 mg/kg), 30-fold of in-
crease of plasma bilirubin was noted within 2 hours in the
rat and this increase was not significant at 24 hrs after in-
jection (basal, 0.01 ± 0.00 mg/dL; 1 hr, 0.34 ± 0.03 mg/dL;
Figure 1 Intraperitoneal injection of bilirubin (BIL) significantly
increase the plasma BIL. *P < 0.05 vs. 0 hours.
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0.06 ± 0.04 mg/dL, P < 0.001) (Figure 1).
Bilirubin (BIL) reduced the urine concentration of kidney
injury molecule-1 (Kim-1) in CsA-induced nephropathy (CIN)
Table 1 shows the physiologic parameters of animals at the
end of experiment. CsA-treated rats presented a significant
increase in serum creatinine (P < 0.01), but this was not
improved by BIL treatment. The excretion of 24-hr urine
albumin was not significantly increased in CsA-treated rats
(5.4 ± 4.1 mg/day, 4.8 ± 5.1 mg/day, 9.1 ± 6.5 mg/day, and
6.6 ± 3.0 mg/day in vehicle (VH), BIL, CsA, and BIL + CsA
groups, respectively). There were no significant differences
in body weight, systolic blood pressure (SBP), lactate de-
hydrogenase (LDH) , AST, and ALT among the groups.
CsA blood level increased in CsA and BIL + CsA groups
(P < 0.01). Serum bilirubin was not increased in VH and
BIL groups at the time of sacrifice, and increased in CsATable 1 Physiologic data a,b
VH
N 5
Body weight (g) 356.5 ± 29.0 35
SBP (mmHg) 127.5 ± 14.0 13
Serum creatinine (mg/dL) 0.7 ± 0.1
24 hr urine albumin (mg) 5.4 ± 4.1
Serum CsA (μg/mL) 0.02 ± 0.00 0
Serum LDH (IU/L) 486.6 ± 183.8 62
Serum AST (IU/L) 79.7 ± 18.9 8
Serum ALT (IU/L) 29.3 ± 3.8 3
Serum bilirubin (mg/dL) 0.03 ± 0.03 0
aVehicle (VH): The rats received a subcutaneous (SC) injection of olive oil 1 ml/kg/d
SC injection of olive oil 1 ml/kg/day plus a intraperitoneal injection of bilirubin (60
injection of CsA 15 mg/kg/day plus a intraperitoneal injection of DMSO; BIL + CsA: T
injection of bilirubin (60 mg/kg) dissolved with DMSO; SBP, systolic blood pressure,
bData are displayed as means ± SD.
*P < 0.05 vs. VH, †P < 0.05 vs. Bil, and ‡P < 0.05 vs. CsA.and BIL + CsA groups (P < 0.01) (Table 1). Urine NGAL
and KIM-1 have been recognized as markers of renal tubu-
lar injuries [23,24]. CsA significantly increased the urine
concentrations of KIM-1 and NGAL (P < 0.05). BIL pre-
treatment reduced the CsA-induced increase of urine
concentration of KIM-1(P < 0.05) (urine KIM-1, 1050.0 ±
261.3 pg/ml, 735.0 ± 120.2 pg/ml, 2278.0 ± 1523.3 pg/ml,
and 858.0 ± 340.3 pg/ml; VH, BIL, CsA, and BIL + CsA,
respectively). In addition, a tendency, although statistically
insignificant, for decreased urine NGAL concentration
was shown in BIL-pretreated rats; urine NGAL, 512.2 ±
451.3 ng/ml, 852.6 ± 536.3 ng/ml, 1457.5 ± 1060.0 ng/ml
and 668.0 ± 345.7 ng/ml; VH, BIL, CsA, and BIL + CsA,
respectively (Figure 2A, 2B).Bilirubin (BIL) ameliorated CsA-induced arteriolopathy
and tubulopathy
BIL treatment ameliorated the histopathologic findings
in CIN. CsA-only treated animals developed an increase
of arteriolar hyalinosis, extensive tubulointerstitial fi-
brosis and tubular injury (P < 0.01) (Figures 3B, 4B). BIL
pretreatment with CsA significantly improved the affe-
rent arteriolopathy, tubulointerstitial fibrosis, and tubular
injury compared to the CsA-only treated rats (P < 0.01)
(Figures 3C, 4C). The semiquantitative scores for arteri-
olar hyalinosis were 0.5 ± 0.0, 0.5 ± 0.0, 1.5 ± 0.4, and 1.0 ±
0.0, in VH, BIL, CsA, and BIL + CsA groups, respectively
(Figure 3D). The scores of tubulointerstitial fibrosis were
0.8 ± 0.3, 0.7 ± 0.3, 1.9 ± 0.2, and 1.2 ± 0.3, and of tubular
injury were 0.5 ± 0.0, 0.5 ± 0.0, 2.4 ± 0.5, and 1.2 ± 0.3,
in VH, BIL, CsA, and BIL + CsA groups, respectively
(Figure 4D, 4E).BIL CsA Bil + CsA
5 5 5
6.1 ± 57.6 318.3 ± 57.6 290.6 ± 10.11
9.8 ± 10.0 149.0 ± 19.8 134.0 ± 15.9
0.7 ± 0.2 1.7 ± 0.9*† 1.7 ± 0.3*†
4.8 ± 5.1 9.1 ± 6.5 6.6 ± 3.0
.02 ± 0.00 2.89 ± 0.29*† 3.31 ± 0.40*†
3.4 ± 400.1 748.2 ± 182.6 642.2 ± 193.6
6.2 ± 41.1 61.6 ± 6.1 66.0 ± 7.0
4.0 ± 17.4 26.4 ± 3.6 31.0 ± 3.3
.01 ± 0.02 0.16 ± 0.04*† 00.20 ± 0.06*†
ay plus a intraperitoneal injection of DMSO; Bilirubin (BIL): The rats received a
mg/kg) dissolved with DMSO; cyclosporine (CsA): The rats received a SC
he rats received a SC injection of CsA 15 mg/kg/day plus a a intraperitoneal
LDH, lactate dehydrogenase.
Figure 2 Urine concentrations of kidney injury molecule-1 (Kim-1) and neutrophil gelatinase-associated lipocalin (NGAL). A: The urine
concentration of Kim-1 is markedly increased in CsA-only treated rats, and is significantly reduced by BIL administration. B: The urine
concentration of NGAL is markedly increased in CsA-only treated rats, and urine NGAL shows a decreasing tendency in BIL-treated rats. The data
are the means ± SD. *P < 0.05 vs. VH, †P < 0.05 vs. BIL, and ‡P < 0.05 vs. CsA.
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species (ROS) in rat kidneys and proximal renal tubular
cells
We determined the activation of NADPH oxidase in re-
sponse to CsA and BIL + CsA treatment in rat kidneys.
CsA treatment increased the expression of NOX4 by
western blotting, although statistically insignificant.
BIL pretreatment markedly reduced the protein level
of NOX4 compared to that of CsA-only treated rats
(P < 0.05) (Figure 5A, 5B). The expression of p22phox
was significantly increased by approximately five foldFigure 3 Afferent arteriolopathy in CsA-treated rat kidneys. A: Vehicle
Semiquantitative scoring of arteriolopathy according to mean percentage o
preglomerular afferent arterioles from the A, B, C and D groups (PAS stain,
arteriolopathy. The data are the means ± SD. *P < 0.05 vs. VH, †P < 0.05 vs. Bin CsA-only treated rats (P < 0.05), and BIL pretreat-
ment improved the expression of p22phox (P < 0.05)
(Figure 5A, 5C). We further examined the effect of
BIL in the generation of ROS. CsA increased the gen-
eration of intracellular ROS revealed by fluorescence
of 2′,7′-dichlorofluorescein in HK-2 cells (Figure 6B).
However, BIL significantly reduced the production of
intracellular ROS (Figure 6C) (P < 0.01). The numbers
of cells with intracellular ROS were 3.1 ± 2.7 cells/
HPF, 23.1 ± 6.0 cells/HPF, and 11.8 ± 3.2 cells/HPF
(Figure 6D).(VH), B: Bilirubin (BIL) C: CsA, and D: BIL + CsA groups E:
f afferent arterioles injured, which was estimated in at least 100
×200). Compared with CsA group, BIL + CsA group displayed afferent
IL, and ‡P < 0.05 vs. CsA.
Figure 4 Tubulointerstitial fibrosis in CsA-treated rat kidneys. A: Vehicle (VH), B: Bilirubin (BIL) C: CsA, and D: BIL + CsA groups (MT staining,
magnification × 200). Semiquantitative scoring of E: tubulointerstitial fibrosis and F: tubular injury according to mean percentage of injured area
obtained in at least 20 fields from the A, B, C and D groups. Compared with CsA group, BIL + CsA group showed improved tubulointerstitial
fibrosis. The data are the means ± SD. *P < 0.05 vs. VH, †P < 0.05 vs. BIL, and ‡P < 0.05 vs. CsA.
Oh et al. BMC Nephrology 2013, 14:105 Page 6 of 12
http://www.biomedcentral.com/1471-2369/14/105BIL improved CsA-induced apoptosis in rat kidney
sections and proximal renal tubular cells
To determine the CSA-induced apoptosis in rat kidneys,
we investigated the kidney sections after having detected
DNA fragmentations with in situ TUNEL assay. In CsA-
only treated rats, the apoptotic cells were markedly in-
creased by the administration of CsA in the rat kidneys
(Figure 7B). A significantly lower number of apoptotic cells
was observed in the BIL-treated rat kidneys (Figure 7C).
The percentages of apoptotic cells were 69.9 ± 3.3 and
37.1 ± 11.7 in CsA and BIL + CsA groups, respectively
(P < 0.01, Figure 7D). The CsA-induced apoptosis appears
to be associated with the intrinsic pathway involving intra-
cellular organelles. Therefore, we investigated the intrinsic
pathway of apoptosis in CsA-treated human proximaltubular cells. The expression of anti-apoptotic bcl-2 and
pro-apoptotic bax was examined by western blotting
(Figure 8A). The administration of CsA significantly re-
duced the abundance of bcl-2 and increased that of bax
(P < 0.05). These changes were recovered in BIL-pretreated
HK2 cells (Figure 8B, 8C). The pro-apoptotic caspase-9
and caspase-3 were also examined by western blotting
(Figure 9A). In CsA-only treated cells, the abundance of
cleaved caspase-9 was significantly increased. In contrast,
BIL pretreatment significantly reduced the abundance of
cleaved caspase-9 (Figure 9B) (P < 0.05). BIL-only treated
group was examined for cleaved caspase-3, and it did
not increase the protein expression of cleaved caspase-3
significantly. CsA increase the expression of cleaved
caspase-3, and BIL treatment reduced that of cleaved
Figure 5 Bilirubin (BIL) suppresses CsA-induced increased expression of Nox4 and p22phox in rat kidneys. A: Western blot analysis of
Nox4 and p22phox molecules from VH, BIL, CsA, and BIL + CsA groups. B: The average densitometric ratio was calculated relative to β-actin for
C: The average densitometric ratio was calculated relative to β-actin for p22phox. The data are the means ± SD. *P < 0.05 vs. VH, †P < 0.05 vs. BIL,
and ‡P < 0.05 vs. CsA.
Figure 6 Bilirubin (BIL) ameliorates intracellular reactive oxygen species (ROS) in CsA-induced nephropathy (CIN). 2′,7′-Dichlorofluorescein
diacetate (DCFH-DA) was used to determine the intracellular production of ROS. A: Vehicle (VH), B: CsA, and C: BIL + CsA groups
(magnification × 400). D: The number of cells with intracellular ROS obtained in at least 10 fields from the A, B and C groups. The data are the
means ± SD. *P < 0.05 vs. control, †P < 0.05 vs. CsA.
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Figure 7 Bilirubin (BIL) ameliorates apoptosis in CsA-induced nephropathy (CIN). Representative TUNEL staining of the renal cortex in CIN.
A: Vehicle (VH), B: Bilirubin (BIL) C: CsA, and D: BIL + CsA groups (magnification × 400). E: The percentage of apoptotic cells (TUNEL-positive cells)
was obtained in at least 10 fields from the A, B and C groups. The data are the means ± SD. *P < 0.05 vs. VH, †P < 0.05 vs. BIL, and ‡P < 0.05 vs. CsA.
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cantly increased in CsA-only treated HK2 cells. BIL pre-
treatment markedly reduced the activity of caspase-3 in
CsA-treated HK-2 cells (P < 0.05, Figure 9D).Discussion
In this study, the protective effect of BIL on CIN was ex-
amined through the inhibition of oxidative stress and
apoptosis. The expression of NADPH oxidase subunits
and intracellular ROS was markedly reduced by BIL ad-
ministration in CsA-treated rat kidneys and HK2 cells,
respectively. BIL ameliorated CsA-induced apoptosis by
up-regulating anti-apoptotic protein bcl2 and down-
regulating pro-apoptotic bax, caspase-9, and caspase-3.The production of ROS, mainly in the form of super-
oxide and hydrogen peroxide, has an important role in the
initiation and progression of cardiovascular and renal dis-
eases [25,26]. The superoxide is generated by univalent re-
duction of molecular oxygen, mediated by various enzyme
systems such as NADPH oxidases of the Nox family. Two
molecules of superoxide react to form hydrogen peroxide
accelerated by the superoxide dismutase [27]. CsA in-
duced the production of superoxide ion and hydrogen
peroxide in kidneys [16,17]. In the present study, the
oxidation of DCFH-DA to fluorescent dichlorofluorescein
(DCF) by ROS was significantly increased in CsA-only
treated HK2 cells [28]. BIL administration effectively re-
duced intracellular ROS in CsA-treated HK2 cells. The
NADPH oxidases have been recently identified as crucial
Figure 8 Bilirubin (BIL) ameliorates apoptosis in CsA-treated HK-2 cells. A: Western blot analysis of bcl-2 and bax molecules from VH, CsA,
and BIL + CsA groups in HK2 cells. B: The average densitometric ratio was calculated relative to β-actin for bcl-2. C: The average densitometric
ratio was calculated relative to β-actin for bax. The data are the means ± SD. *P < 0.05 vs. control, †P < 0.05 vs. CsA.
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NADPH oxidases were performed in phagocytic cells. The
NADPH oxidases on phagocyte are composed of two
plasma membrane-associated proteins, gp91phox and
p22phox, which form flavocytochrome b558, and cytosolic
subunits, p40phox, p47phox, p67phox, and the small GTPase
Rac1/2. Nox proteins had been found as homologs of
gp91phox in renal cells [28]. The most highly expressed
Nox homolog in cardiorenal system is Nox4 [31,32],
which is abundant in renal tubule, fibroblast, and
glomerular mesangial cells [33-35]. Increasing evidence
suggests that Nox 4 heterodimerization with p22phox is
sufficient to activate the enzyme without any cytosolic fac-
tors, contrary to other Nox isoforms [32,36]. In addition,
the overall output of ROS may be directly related to the
expression level of Nox4 [32]. We confirmed that Nox4
and its docking subunit p22phox are increased by adminis-
tration of CsA. CsA increased Nox2 mRNA and proteins
in rat tubular epithelial cells, and Nox-2 and p22phox
were increased in tubulointersitial injury in human allo-
grafts [37,38]. However, BIL reduced the protein expres-
sion of Nox4 and p22phox in CsA induced renal injury.
The production of oxidative stress may play a principal
role in the process of tubular injury [39,40]. HO-1 is the
rate-limiting enzyme of heme degradation, and heme is
converted to CO and bilirubin by HO-1. HO-1 had
showed antioxidant, anti-inflammatory, and cytoprotective
effect. HO-1 induction by heme arginate and the treat-
ment of bilirubin attenuate TNF-alpha mediated VCAM-1
production, however, CO did not show the beneficial ef-
fect. This data suggest that the anti-atherogenic effect
of HO-1 is mediated predominantly by the action ofbilirubin [41]. HO-1 is expressed at low levels within the
normal kidney and the HO-1 is induced in response to
tubulointerstitial injury [42]. In addition, exogenous biliru-
bin treatment resulted in improvements in renal vascular
resistance, glomerular filtration rate, tubular function, and
urine output after ischemia-reperfusion injury. Exogenous
bilirubin accumulated within the hepatoblastoma HepG2
cells [43].
The apoptosis in renal tubular cells causes tubular dila-
tation and atrophy in renal injury [44]. Apoptosis is ini-
tiated by two distinct pathways: an intrinsic pathway
involving mitochondria and an extrinsic pathway leading
to the rapid recruitment of Fas-Associated protein with
Death Domain and caspase-8 [45]. The apoptosis induced
by CsA may be developed through the intrinsic pathway,
because it promotes Bax aggregation and translocation to
the mitochondria, inducing permeabilization of the outer
mitochondrial membrane and release of cytochrome C
[45]. In addition, CsA causes a caspase-dependent loss of
mitochondrial membrane potential, and activation of
caspase-9 and caspase-3 [45,46]. In this study, CsA in-
creased the number of apoptotic cells in rat kidneys, and
consequently increased the expression of bax, cleaved
caspase-9, cleaved caspase-3 and the activity of caspase-3.
In addition, the anti-apoptotic bcl-2 protein, which se-
questers Bax and inhibits the activation of caspase-9, was
reduced by CsA treatment. However, these alterations
were recovered by BIL treatment in CIN.
Kim-1 and NGAL have been proposed as kidney in-
jury markers [23,24]. Kim-1 is a type 1 transmembrane
glycoprotein with an immunoglobulin and mucin do-
main, and NGAL is a protein of the lipocalin family
Figure 9 Bilirubin (BIL) suppresses CsA-induced apoptosis in HK-2 cells. A: The protein expression of cleaved caspase-9 and cleaved
caspse-3 from VH, CsA, BIL, and BIL+CsA groups in HK2 cells. B: The average densitometric ratio was calculated relative to β-actin for cleaved
caspase-9. C: The protein expression of cleaved caspse-3 from VH, CsA, BIL, and BIL+CsA groups in HK2 cells. D: The average densitometric ratio
was calculated relative to β-actin for cleaved caspase-3. E: Caspase-3 activity was determined by caspase-3 fluorometric assay in HK2 cells. The
data are the means ± SD. *P<0.05 vs. control, †P<0.05 vs. CsA.
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calyx [23,24]. After renal injury, they are highly up-
regulated in damaged renal proximal tubular cells, and
can be detected in urine. The degree of renal injury is
correlated with the increased urine concentration of
NGAL and Kim-1 [23,24,47,48]. The functions of Kim-1
and NGAL are unclear, but their relations with apop-
tosis have been documented [48-50]. According to the
severity of renal damage, both the number of apoptotic
cells and the expression of Kim-1 were increased, and
Kim-1 was expressed in all the tubules displaying apop-
totic labeling [47]. In addition, the up-regulation of
Kim-1 and NGAL was identified in CsA-induced renal
injury, suggesting that renal tubular cells are injured by
CsA [51,52]. We confirmed the reno-protective effect of
BIL by the significant reduction of urine Kim-1 and the
decreased tendency of urine NGAL concentration, indi-
cating that BIL helps to prevent epithelial cell injury.Histologic improvements in arteriolopathy, tubulo-
interstitial fibrosis, and tubular injury were found in
BIL-treated rat kidneys, and these recoveries appeared
to be associated with the reduction of oxidative stress,
apoptosis, and tubular damage. The administration of
bilirubin could be a target for protecting against the
progression of renal injury, but further studies will be
needed to facilitate such a potential therapy.Conclusions
We showed that the direct administration of BIL protected
against CsA-induced tubular injury via inhibition of oxida-
tive stress and apoptosis. BIL may be a protective agent
against renal tubular injury, but further studies are needed
to develop this potential therapy.
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